LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

3.21 2.88

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.12

Max

3.29

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.3M -3M
Verkäufe	100K 100K
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-16M 23M
Vorheriger Eröffnungskurs	0.33
Vorheriger Schlusskurs	3.21

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Mai 2026, 23:41 UTC

Ergebnisse

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. Mai 2026, 21:40 UTC

Ergebnisse

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. Mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. Mai 2026, 23:12 UTC

Ergebnisse

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:07 UTC

Ergebnisse

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. Mai 2026, 23:05 UTC

Ergebnisse

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. Mai 2026, 23:04 UTC

Ergebnisse

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. Mai 2026, 22:50 UTC

Ergebnisse

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. Mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. Mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. Mai 2026, 21:58 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:47 UTC

Market Talk

Ergebnisse

Costco Posts 13% Sales Growth in April -- Market Talk

6. Mai 2026, 21:46 UTC

Ergebnisse

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. Mai 2026, 21:40 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. Mai 2026, 21:32 UTC

Heiße Aktien

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. Mai 2026, 21:29 UTC

Ergebnisse

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.